| Title: | Deletion of the pro-adipogenic factor Zinc Finger Protein 467 (Zfp467), which induces high bone mass, protects mice from high fat diet-induced obesity |
| Authors: | Le, P Vegting, Y Rosen, C Martin, J Baron, R |
| Issue Year: | 2019 |
| Publisher | WILEY |
| Series | JOURNAL OF BONE AND MINERAL RESEARCH: |
| Abstract | Olanzapine (OLZ) is a second-generation antipsychotic that is used to treat schizophrenia but also causes acute hyperglycemia. This study aimed to determine if the ablation of AMPK beta 1-containing complexes potentiates acute OLZ-induced metabolic dysfunction and if the activation of AMPK beta 1 suppresses these effects. Female AMPK beta 1(-/-) or wild-type (WT) control mice were treated with OLZ, and changes in blood glucose, serum and liver metabolites, whole-body fuel oxidation, and pyruvate-induced increases in blood glucose were measured. Additionally, WT mice were cotreated with OLZ and A769662, a specific AMPK beta 1 activator, and we determined if cotreatment protected against acute, OLZ-induced metabolic dysfunction. OLZ-induced increases in blood glucose were exacerbated in AMPK beta 1 mice compared with WT mice, and this was paralleled by greater OLZ-induced increases in markers of liver glucose production, such as pyruvate tolerance, serum glucagon, and glucagon responsiveness. Cotreatment with A769662 attenuated OLZ-induced increases in blood glucose, serum nonesterified fatty acid, and glycerol. Furthermore, this effect was absent in AMPK beta 1(-/-) mice, consistent with A769662's specificity for the AMPK beta 1 subunit. Reductions in AMPK activity potentiate the effects of acute OLZ treatment on blood glucose, whereas specifically targeting AMPK beta 1-containing complexes is sufficient to protect against OLZ-induced hyperglycemia. |
| URI: | https://publications.svi.edu.au/publications/7491 |
| Other Identifiers | |
| Publication type | Meeting Abstract |